Institutional Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Institutional Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$15.3M	Sell	421,073 -251,310	-37%	-$10M	0.23%	47
2016 Q3	$45.6M	Sell	672,383 -4,150,176	-86%	-$217M	0.63%	40
2016 Q2	$242M	Sell	4,822,559 -487,675	-9%	-$26M	2.97%	14
2016 Q1	$284M	Buy	5,310,234 +212,242	+4%	+$12.5M	3.02%	18
2015 Q4	$335M	Buy	5,097,992 +4,361,352	+592%	+$270M	2.9%	17
2015 Q3	$41.6M	Buy	+736,640	New	+$47.8M	0.35%	44
2013 Q4	–	Sell	-2,245,550	Closed	-$84.8M	–	48
2013 Q3	$84.8M	Buy	2,245,550 +1,013,350	+82%	+$39.5M	0.43%	40
2013 Q2	$48.3M	Buy	+1,232,200	New	+$48M	0.25%	41

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Institutional Capital's TEVA Position: Q4 2016 in Review

Institutional Capital reduced its Teva Pharmaceuticals (TEVA) stake by 37% in Q4 2016, selling an estimated $10M and leaving 421,073 shares worth $15.3M. The position accounts for 0.23% of the portfolio, ranked #47.

Institutional Capital first reported a position in TEVA in Q2 2013 and has held it in 8 quarters since. The position peaked at $335M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Institutional Capital held 421,073 shares of Teva Pharmaceuticals worth $15.3M as of Q4 2016.
Institutional Capital sold 251,310 Teva Pharmaceuticals shares in Q4 2016, an estimated $10M.
Teva Pharmaceuticals made up 0.23% of Institutional Capital's portfolio in Q4 2016, its #47 holding.
Institutional Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
Institutional Capital's Teva Pharmaceuticals position peaked at $335M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Institutional Capital's 13F filing for Q4 2016, filed 2 Feb 2017.